According to a recent study conducted by researchers at Harvard Medical School and Beth Israel Deaconess Medical Center, 76 percent of the adverse side effects (such as fatigue or headache) that people experienced after receiving their first COVID-19 vaccination were also reported by participants who received a placebo shot.
UK Variant Not as Lethal as Originally Reported
Antibody-Drug Conjugates (ADCs), Breast Cancer, Brown Fat Cells, Cancer Immunology Research, COVID-19 Deaths, COVID-19 Variant B.1.1.7, Covid-19 Variants, Fat Cells, Harvard Medical School, Hospitalized COVID-19 Patients, Immune Cells, Lancet Infectious Diseases, Lancet Public Health, Massachusetts General Hospital, MD Anderson Cancer Center, Osteosarcoma, SARS-CoV-2 virus, Skin Cancer, T-Cells, The Ohio State University Wexner Medical Center, Tumors, WuhanA new study by researchers at the University College London (UCL) published in Lancet Infectious Diseases finds that although the U.K. variant of SARS-CoV-2 known as B.1.1.7 is more transmissible than the wild-type, original Wuhan strain, it is likely not more deadly.
A new study published in Nature suggests that with a cellular and molecular map of the healthy human heart, experts may be able to better understand what goes wrong in cardiovascular disease.
New Research Sheds Light on the Temporary Loss of Smell Stemming from Covid-19
ACE2 (angiotensin-converting enzyme-2), Clinical Trials, Coronavirus Disease 2019 (COVID-19), Electronic Health Records, Harvard Medical School, JAMA Otolaryngology Head and Neck Surgery, Medical Schools, Neuroscience, Olfactory Neurons, Proteins, R&D, Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), Smell, Symptoms: Coronavirus Disease 2019 (COVID-19), TasteAccording to a study published in the journal Science Advances, an international team of researchers led by neuroscientists at Harvard Medical School uncovered which olfactory cell types are most vulnerable to infection by SARS-CoV-2, which causes Covid-19.